Japan / The Latest Therapeutic Applications in Induced Pluripotent Stem Cell (iPSC) Technology
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how a technology developed in Japan…
Anders Blanck of Lif, the trade association for the research-based Swedish pharmaceutical industry, outlines the steps already being put in place for Sweden to become a leading country in the…
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how a technology developed in Japan…
On 7 October 2020, the 2020 Nobel Prize in Chemistry was jointly awarded to Emmanuelle Charpentier and Jennifer A.…
Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in…
Photo: Sofia Linden / Oslo Cancer Cluster Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team is conducting at Oslo University Hospital. Kyte also explores how Norway can better develop its clinical footprint and what his hopes for the future of experimental cancer treatment in the country are. [Norway] should stop thinking…
Below we present a list of the top 5 public biopharma companies that focus on developing RNA-based therapies. RNA…
On 7 October 2020, the 2020 Nobel Prize in Chemistry was jointly awarded to Emmanuelle Charpentier and Jennifer A.…
Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T…
Anders Blanck of Lif, the trade association for the research-based Swedish pharmaceutical industry, outlines the…
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how a technology developed in Japan…
On 7 October 2020, the 2020 Nobel Prize in Chemistry was jointly awarded to Emmanuelle Charpentier and Jennifer A.…
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced,…
In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy…
Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but…
Rare diseases and cell and gene therapy executive recruitment specialist Steve Smith outlines six key strategies…
David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in the cell and…
Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T…
Medicare, a national health insurance program in the United States covering Americans aged 65 and older as well as…
France – one of the most influential countries in the development of gene therapy– still stands as a global…